Morphea Scleroderma PDF Print E-mail
Wednesday, 09 December 2009 14:48
taken from http://dermnetnz.org/immune/img/morph2-s.jpgMorphea, is one of two types of localized Scleroderma, and a disorder characterized by excessive collagen deposits leading to thickening of the dermis, subcutaneous tissues, or both. The cause of Scleroderma is unknown. It is important to remember that it is not contagious, nor inherited or passed on from one generation to the next, except in rare circumstances. We do know that in Scleroderma, the body produces too much of a protein called collagen.

Morphea is classified into plaque, generalized, linear, and deep subtypes according to the clinical presentation and depth of tissue involvement.

Unlike Systemic Sclerosis, Morphea lacks features such as Sclerodactyly, Raynaud's phenomenon, and internal organ involvement. Saleh et al (2009) discussed a new variant, termed Superficial Morphea, which is characterized clinically by hyperpigmented or hypopigmented patches of skin that lack induration.

taken from http://www.lib.uiowa.edu/HARDIN/MD/pictures22/dermnet/morphea61.jpgEarly Morphea Scleroderma has an inflammatory stage, followed by one or more slowly enlarging patches or plaques. These plaques are most commonly oval in shape and vary in size. They have an ivory/yellow center and are surrounded by a violet colored area.

The violet color signifies that the Scleroderma is in a state of activity. The plaques feel firm and hard, but are not deeply bound down. They may be depressed or slightly elevated and are seen more often on the trunk, but may also occur on the face and extremities.

An uncommon form of Morphea is the guttate variety. It is characterized by multiple, small, chalk-white spots which vary in size from 1 to 10mm in diameter. The violet-colored line may surround all or some of the spots and in cases of long duration the line may be brown or grayish. Guttate Morphea primarily involves the chest, neck and shoulders, and only occasionally other parts of the body. Localized Morphea may last from a few months to many years. However, a large proportion of Morphea patients improve spontaneously.

The following are some excellent resources, which have additional information and images on Morphea Scleroderma. You can  read more about treatments, types, and associated complications.

HealthCentral.com (2009), "Morphea Scleroderma". http://www.healthcentral.com/encyclopedia/408/37.html
HealthScout (2009), "Morphea Scleroderma". http://www.healthscout.com/ency/68/37/main.html
EMedicine (2009), "Morphea". http://emedicine.medscape.com/article/1065782-overview
AOCD (2009), "Morphea". http://www.aocd.org/skin/dermatologic_diseases/morphea.html
MayoClinic (2009), "Morphea". http://www.mayoclinic.com/health/morphea/DS00718/DSECTION=symptoms

 
More articles :

» Top 10 Scleroderma Stories For 2012

For the hundreds of thousands of people around the world, living with Scleroderma can be particularly challenging. As part of the Foundation's ongoing mission, we seek to source and provide useful information, tips, and articles which can help...

» The Mississauga Support Group To Host Annual Fundraiser

The Mississauga Support Group of the Scleroderma Society of Ontario will host its annual fundraising dinner and dance gala on April 2 at the Oasis Convention Centre. Funds raised will go to the Scleroderma Society of Ontario to fund research,...

» Pathogenesis and Therapeutic Approaches for Improved Topical Treatment in Localized Scleroderma and Systemic Sclerosis

I. Badea; M. Taylor; A. Rosenberg; M. FoldvariPosted: 09/03/2009; Rheumatology. 2009;48(3):213-221. © 2009 Oxford University PressSSc is a chronic progressive disorder of unknown aetiology characterized by excess synthesis and deposition of...

» Prevention Of Vascular Damage In Scleroderma With Angiotensin-converting Enzyme (ACE) Inhibition

Great strides have been made in identifying and managing the organ-based complications of  systemic sclerosis (SSc). There is no room for the nihilism towards treating this disease that used to be so prevalent. However, there is still...

» Scleroderma Study Identifies Roadblocks To Employment

In the United States, the work disability rate for people with , also known as systemic sclerosis, is two to three times that of people with some other rheumatic conditions, according to research data from investigators at The (UTHealth) Medical...

» The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

Marta Baleva and Krasimir NikolovReceived 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in Scleroderma is...